Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis.
- DOI
- 10.1186/s12876-022-02347-1
- Published
- 2022 Jun 8
- Container
- BMC gastroenterology
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1186/s12876-022-02347-1,
title = {Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis.},
author = {Peyrin-Biroulet L and Arkkila P and Armuzzi A and Danese S and Guardiola J and Jahnsen J and Lees C and Louis E and Lukáš M and Reinisch W and Roblin X and Jang M and Byun HG and Kim DH and Lee SJ and Atreya R},
year = {2022},
journal = {BMC gastroenterology},
doi = {10.1186/s12876-022-02347-1},
url = {https://doi.org/10.1186/s12876-022-02347-1}
}RIS
TY - JOUR TI - Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis. AU - Peyrin-Biroulet L AU - Arkkila P AU - Armuzzi A AU - Danese S AU - Guardiola J AU - Jahnsen J AU - Lees C AU - Louis E AU - Lukáš M AU - Reinisch W AU - Roblin X AU - Jang M AU - Byun HG AU - Kim DH AU - Lee SJ AU - Atreya R PY - 2022 JO - BMC gastroenterology DO - 10.1186/s12876-022-02347-1 UR - https://doi.org/10.1186/s12876-022-02347-1 ER -
APA
L, P., P, A., A, A., S, D., J, G., J, J., C, L., E, L., M, L., W, R., X, R., M, J., HG, B., DH, K., SJ, L., & R, A. (2022). Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis.. BMC gastroenterology. https://doi.org/10.1186/s12876-022-02347-1
Source records
- pubmed · retrieved 2026-11-10T13:47:23.607Z